sorafenib has been researched along with nutlin-3a in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (nutlin-3a) | Trials (nutlin-3a) | Recent Studies (post-2010) (nutlin-3a) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 698 | 1 | 504 |
| Protein | Taxonomy | sorafenib (IC50) | nutlin-3a (IC50) |
|---|---|---|---|
| Protein Mdm4 | Homo sapiens (human) | 4.6273 | |
| Cellular tumor antigen p53 | Homo sapiens (human) | 1.0388 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.07 | |
| E3 ubiquitin-protein ligase Mdm2 | Homo sapiens (human) | 0.1832 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awasthi, S; Nagaprashantha, LD; Singhal, J; Singhal, SS; Vatsyayan, R | 1 |
| Celeghini, C; di Iasio, MG; Lanza, F; Melloni, E; Ongari, M; Secchiero, P; Tiribelli, M; Voltan, R; Zauli, G | 1 |
| Sattler, M; Weisberg, E | 1 |
| Brors, B; Haibe-Kains, B; Kurilov, R | 1 |
1 trial(s) available for sorafenib and nutlin-3a
| Article | Year |
|---|---|
The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Topics: Antineoplastic Agents; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Imidazoles; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Piperazines; Sorafenib; Tumor Suppressor Protein p53 | 2012 |
3 other study(ies) available for sorafenib and nutlin-3a
| Article | Year |
|---|---|
Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Benzenesulfonates; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cell Movement; Humans; Imidazoles; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyridines; Sorafenib; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.
Topics: Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Piperazines; Sorafenib; Tumor Suppressor Protein p53 | 2012 |
Assessment of modelling strategies for drug response prediction in cell lines and xenografts.
Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |